Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will DexCom (DXCM) Beat Estimates Again in Its Next Earnings Report?

LONDON--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in continuous glucose monitoring for people with diabetes, today announced the UK launch of its Time in Range Campaign, an awareness and education campaign to improve the understanding and accelerate the adoption of time in range as the standard of care in diabetes management. A recent UK survey found that despite its clinical and quality-of-life benefits, the majority of people with insulin-treated diabetes are not using ti

Dexcom Expands Time in Range Initiative with Nick Jonas to Help Improve the Lives of People with Diabetes in the UK

GrowGeneration Corp

Both companies are in industries with strong opportunity ahead.

Got $1,000? These 2 High-Growth Stocks Are Screaming Buys Right Now

Investors continue to be optimistic about DexCom (DXCM) owing to its slew of favorable coverage decisions for its G6 CGM System.

Here's Why You Should Add DexCom (DXCM) Stock to Your Portfolio

SAN DIEGO--(BUSINESS WIRE)--Dexcom Schedules Third Quarter 2021 Earnings Release and Conference Call for October 28, 2021 at 4:30 p.m. Eastern Time.

Dexcom Schedules Third Quarter 2021 Earnings Release and Conference Call for October 28, 2021 at 4:30 p.m. Eastern Time

Organogenesis Holdings

Progyny

Their products are better than those of their rivals, and their leads are increasing.

3 Innovative Growth Stocks That'll Make You Richer Through 2025

Dexcom's (DXCM) CGM System is expected to simplify diabetes management due to increasing access to the life changing technology.

Dexcom's (DXCM) G6 CGM System Gets Coverage in Manitoba

The stock isn't a household name, but it's generated multibagger returns over the past five years alone.

1 Supercharged Healthcare Stock to Buy Right Now

We think that Dexcom stock currently is a better pick compared to Abbott stock, despite Dexcom being more expensive of the two. Dexcom trades at about 25x trailing revenues, compared to just 5x for Abbott.

This Stock Is Likely To Outperform Abbott Laboratories

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom G6 Continuous Glucose Monitoring System now Covered in Manitoba for Young People With Type 1 Diabetes

Dexcom G6 Continuous Glucose Monitoring System Now Covered in Manitoba for Young People With Type 1 Diabetes

Netflix

The performance of these two companies isn't detached from their financial results.

Ignore GameStop: Here Are 2 Better Stocks

A few months back we discussed that going by its historical performance Dexcom Stock may continue to rally after a 23% rise in a month. DXCM stock has since rallied 34%, while it is up 11% over the last one month close to its all-time high levels of $579.

Will Dexcom Stock Continue To Make Fresh Highs?

Illumina

Teladoc

Veeva Systems

The merging of healthcare and technology is changing how we care for our bodies. It's also creating investment opportunities, such as these five medical technology stocks.

5 Medtech Stocks to Seize Major Growth

Expanded access to Dexcom's (DXCM) G6 CGM for clients enrolled in NIHB is expected to aid a wider patient pool to better manage their diabetes.

Dexcom's (DXCM) G6 CGM Under NIHB Program to Aid More Patients

BURNABY, British Columbia--(BUSINESS WIRE)--Non-Insured Health Benefits Program now Covers Dexcom G6 CGM System for Children and Adolescents on Intensive Insulin Therapy

Non-insured Health Benefits Program Now Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adolescents on Intensive Insulin Therapy

A smart monitor company that received FDA approval in 2015 has seen a five-year stock performance that has outperformed the returns of Apple Inc (NASDAQ: AAPL), Alphabet Inc (NASDAQ: GOOG)(NASDAQ: GOOGL) and Amazon.com, Inc. (NASDAQ: AMZN). The company's five-year outlook and guidance show that shares could see another strong return in the next five years.

This Smart Monitor Company Has Outperformed Apple, Google And Amazon Over The Last 5 Years

Align Technology

Intuitive Surgical

Their competition is in the rearview mirror, and customers are clamoring for their products.

3 Growth Stocks That'll Make You Richer By 2024

Despite a mixed Q2 2021 result, bullish sentiment is building for Senseonics. Here's why SENS stock can run-up in the future.

Senseonic Stock Is Climbing After Bouncing Back From a Disappointing Q2

Moderna

U.S. indices had a mixed day of trading Wednesday as investors weigh rising COVID-19 Delta variant cases nationwide. The Invesco QQQ Trust Series 1 (NASDAQ: QQQ) gained 0.17% to $380.58

Moderna And DexCom Lead The Nasdaq-100

Invesco QQQ

O'Reilly Automotive

U.S. indices bounced off Monday morning's lows as investors weigh weak China retail and production data. Uncertainty around the COVID-19 Delta variant is also weighing on the market.

DexCom And O'Reilly Auto Parts Lead The QQQ Monday

FedEx

These companies are still going to be great long-term buys.

3 Growth Stocks to Buy and Hold Regardless of What Happens With the Delta Variant

Pinterest

These two stocks have been moving in opposite directions of late.

2 Top Growth Stocks That Could Help Your Portfolio Shine

Lululemon Athletica

Insulet

Athletic-apparel maker Lululemon and two diabetes specialists are poised to get a long-term tailwind from the COVID-19 pandemic.

3 Stocks to Buy That Should Get a Boost From Pandemic-Driven Consumer Weight Gain

KLA-Tencor

Many investors probably haven't even have heard of these big winners.

These 2 Winning Stocks Came Out of Nowhere Friday

Continuous glucose monitor developer Dexcom Inc (NASDAQ: DXCM) shares ticked up as second-quarter results easily topped the consensus forecast; adjusted EPS of 0.76 beat the consensus of $0.45. Sales increased 32% Y/Y $595.1 million, well ahead of the estimate of $551.3 million.

News for DexCom Stock (DXCM)